VU Research Portal
The evolving treatment of ankylosing spondylitis
van Denderen, J.C.
2015
document version
Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
van Denderen, J. C. (2015). The evolving treatment of ankylosing spondylitis.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
promotor: prof.dr. J.W.J. Bijlsma
copromotoren: dr. I.E. van der Horst-Bruinsma dr. M.T. Nurmohamed
CONTENTS
Chapter 1 Introduction:
1. General introduction.
2. History of the disease ankylosing spondylitis. 3. History of therapy in ankylosing spondylitis. 4. Objectives and outline of this thesis.
8 11 21 29
Chapter 2 Efficacy and safety of mesalazine (Salofalk®) in an open study
of 20 patients with ankylosing spondylitis.
41
Chapter 3 Statin therapy might be beneficial for treating patients with ankylosing spondylitis.
51
Chapter 4 Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis.
57
Chapter 5 Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
71
Chapter 6 Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept.
81
Chapter 7 What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function.
95
Chapter 8 Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis.
107
Chapter 9 Etanercept increases bone mineral density in ankylosing spondylitis, but does not prevent the increase of vertebral fractures.
121
Chapter 10 1. General discussion and summary. 2. Nederlandse samenvatting. 3. Dankwoord.
4. Curriculum vitae. 5. List of publications.
6. List of abbreviations and illustrations.
